**Guideline Page and Request**

**Internal request:** Evaluate the data supporting cemiplimab-rwlc as a first-line treatment option for patients with metastatic NSCLC (adenocarcinoma and squamous cell carcinoma), PD-L1 (≥50%), negative for actionable biomarkers, and PS 0-2.

**External request:** Submission from Regeneron Pharmaceuticals, Inc., requesting the addition of cemiplimab-rwlc as a preferred first-line treatment option for patients with metastatic NSCLC, PD-L1 (≥50%), negative for actionable biomarkers, and PS 0-2 for both Adenocarcinoma and Squamous cell carcinoma.

**Panel Discussion/References**

Based on the data in the noted references, the Panel consensus supported the addition of cemiplimab-rwlc as a preferred first-line treatment option for patients with metastatic NSCLC (adenocarcinoma and squamous cell carcinoma), PD-L1 (≥50%), negative for actionable biomarkers, and PS 0-2. This is a category 1 recommendation.


- See Submission for references.

**Institution Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>1</td>
<td>2</td>
<td>7</td>
</tr>
</tbody>
</table>